Show simple item record

Authordc.contributor.authorValenzuela Báez, Rodrigo 
Authordc.contributor.authorVidela Cabrera, Luis 
Admission datedc.date.accessioned2018-11-13T16:53:52Z
Available datedc.date.available2018-11-13T16:53:52Z
Publication datedc.date.issued2018-06
Cita de ítemdc.identifier.citationPharmacological Research 132 (2018) 168–175es_ES
Identifierdc.identifier.other10.1016/j.phrs.2017.12.013
Identifierdc.identifier.urihttp://repositorio.uchile.cl/handle/2250/152589
Abstractdc.description.abstractNormal liver function includes a number of metabolic processes, secretion of cellular mediators and its role in immunobiology; these require a high energy supply, which is further enhanced under adverse conditions triggering hepatic disorders or injury due to the operation of counteracting mechanisms. Alterations in oxygen availability, such as ischemia-reperfusion (IR) leading to liver inflammation and high-fat diet (HFD)-induced hepatic steatosis, are noxious responses encountered in hepatic surgery and obesity, respectively. Several strategies have been developed to attenuate or prevent these disorders, including thyroid hormone (T-3), docosahexaenoic acid (DHA) and extra virgin olive oil (EVOO). These hormetic agents that exert beneficial effects in the low dose range were shown to abrogate IR-induced liver injury effectively in the case of T-3, DHA, or their combined administration, whereas DHA plus EVOO attenuate HFD-induced hepatic steatosis, although they can induce adverse effects in other experimental settings. The use of combined hepatoprotective protocols (DHA + T-3 or DHA + EVOO) using low doses or reduced supplementation periods is characterized by the stimulation of different types of molecular defensive mechanisms and similar signaling processes that exhibit synergism, thus constituting suitable experimental liver pharmacological preconditioning strategies with possible future clinical applications. (C) 2017 Elsevier Ltd. All rights reserved.es_ES
Patrocinadordc.description.sponsorshipThis work was supported by grant 1150104 from the National Fund Scientific & Technological Development (FONDECYT, Chile, to LAV).es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherElsevieres_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourcePharmacological Researches_ES
Keywordsdc.subjectHepatoprotectiones_ES
Keywordsdc.subjectThyroid hormonees_ES
Keywordsdc.subjectPreconditioninges_ES
Keywordsdc.subjectDocosahexaenoic acides_ES
Keywordsdc.subjectExtra virgin olive oiles_ES
Keywordsdc.subjectSteatosis attenuationes_ES
Keywordsdc.subjectAMP-activated protein kinasees_ES
Títulodc.titleCrosstalk mechanisms in hepatoprotection: thyroid hormone-docosahexaenoic acid (DHA) and DHA-extra virgin olive oil combined protocolses_ES
Document typedc.typeArtículo de revistaes_ES
Catalogueruchile.catalogadorrvhes_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile